Recognizing the Early Signs of Anemia

Anemia (an inadequate supply of red blood cells) can cause symptoms such as fatigue, shortness of breath, and dizziness. Other possible signs of this condition [...]

Interim PET Scans May Improve Treatment for Esophageal Cancer

Clinical trial results presented at the 2017 Gastrointestinal Cancers Symposium in San Francisco suggest that the use of PET scans to assess a cancers response [...]

Personalized Treatment with Erbitux in Head and Neck Cancer Promising

Researchers from UCLA have reported that a short course of the drug Erbitux® (cetuximab) in combination with standard chemotherapy and radiation improves survival in individuals [...]

Imbruvica® is approved by FDA for Marginal Zone Lymphoma

The U.S. Food and Drug Administration (FDA) has approved Imbruvica® (ibrutinib) for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy [...]

Opdivo (nivolumab) Improves Survival in Patients with Advanced Gastric Cancer

At the 2017 Gastrointestinal Cancers Symposium in San Francisco researchers presented new trial results demonstrating that Opdivo (nivolumab) significantly reduced the risk of death by 37% in [...]

2016-Year in Review: Advances in Management of Gastric & Esophageal Cancer

Advances in the management of stomach (gastric), and esophageal cancer have been slow. Each year in the United States, more than 17,000 people are diagnosed [...]

Early Treatment in Smoldering Myeloma Improves Long-Term Outcomes

Use of the treatment combination consisting of Revlimid (lenalidomide) plus dexamethasone during smoldering myeloma appears to significantly improve long-term outcomes for patients. These results were [...]

2016-Year in Review: Top Advances in Management of Melanoma

2016 was a year of continued advances in the management of melanoma as a result of advances in precision medicine and immunotherapy. Trial results matured [...]

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple [...]

Lung Cancer Treatment Gets Personal

Recent advances highlight the power of precision medicine. By Charles H. Weaver, MD Recently, there have been more exciting new approaches to managing non–small cell [...]

« More News Tips & Features